UBI集團訊息
UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing Facility
This facility consists of eight floors with a total floor area of about 22,000 square meters, including research & process development laboratories and a manufacturing facility for protein pharmaceuticals. Currently, two 2,000-liter mammalian cell-based production lines are built with state-of-the-art single-use process technology. Space is reserved allowing for future expansion of up to 12 lines in total.
Such proprietary research and manufacturing capacity expedites product development and clinical progress for the mAb therapeutic pipeline, significantly reduces outsourcing manufacturing costs, and generates revenue through recently launched contract development and manufacturing services. Most importantly, the facility will also manufacture UBP’s leading product, UB-421 (anti-AIDS mAb), for phase III clinical trial.
The new facility UBP a leader in Taiwan by total production capacity for GMP protein drug manufacturing. UBP will continue to synergize its advantages of 10+ years of protein drug manufacturing experience in its pilot plant, proprietary and advanced protein drug technology, and economy of scale with this industry-scale manufacturing capability. UBP continues to strive to become a global leader in developing, manufacturing and commercializing monoclonal antibody medicines.
About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind.
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.